Welcome to our dedicated page for Senti Biosciences Holdings SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senti Biosciences SEC filings document a clinical-stage biotechnology issuer built around the Gene Circuit platform and its cell-therapy pipeline. The company’s 8-K reports cover operating and financial results, corporate updates, clinical or regulatory disclosures, shareholder voting matters, governance items, capital-structure matters and material agreements, including research-and-development laboratory lease disclosures.
The filing record also includes a Form 15-12G for Senti Biosciences, Inc. after a completed Delaware holding company reorganization under which Senti became a subsidiary within Senti Biosciences Holdings. That filing addresses termination or suspension of Exchange Act registration and reporting duties for the covered Senti common stock, alongside the issuer’s corporate-status and security-class disclosures.
Senti Biosciences (SNTI) filed its Q3 2025 10‑Q, reporting a net loss of $18.1 million for the quarter and $47.0 million for the nine months. Cash and cash equivalents were $12.2 million at September 30, 2025, down from $48.3 million at year‑end, and management concluded that substantial doubt exists about the company’s ability to continue as a going concern without additional financing.
Operating expenses were $16.9 million in Q3, driven by R&D $10.5 million and G&A $6.4 million. Net cash used in operating activities was $36.6 million for the nine months. The company also recorded a $3.3 million reversal of previously recognized sublease income tied to related‑party GeneFab after determining collectibility was not probable. As of quarter‑end, GeneFab owed $4.7 million in past‑due sublease rent; $1.0 million was received in October.
Senti received a default notice on its Alameda lease for ~$0.4 million of unpaid rent; discussions to cure are ongoing and the lease remains in place. The company converted 21,157 shares of Series A preferred into 21,157,000 common shares in March 2025. Shares outstanding were 26,290,838 as of October 31, 2025. CIRM grant receipts totaled $7.4 million to date, supporting the SENTI‑202 program.
Senti Biosciences (SNTI) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company reported this via an Item 2.02 Form 8-K dated November 13, 2025, with the press release attached as Exhibit 99.1.
Consistent with General Instruction B.2., the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into Securities Act filings.
Celadon Partners disclosed a 45.0% beneficial ownership stake in Senti Biosciences, Inc. (SNTI), reporting ownership of 13,404,441 shares, which includes 3,627,441 shares issuable upon exercise of warrants subject to a 45% ownership cap. The percentage is calculated using 26,160,206 shares outstanding as of July 31, 2025. The filing (Amendment No. 2 to Schedule 13D) states Celadon intends to continue preliminary discussions with Senti about a potential financing and may seek changes to capital structure and Board composition, including potential additional Board representation. Celadon also reserves the right to buy or sell securities or pursue hedging or other actions as circumstances evolve.
Event: Senti Biosciences, Inc. (SNTI) filed a Form 4 reporting that director James J. Collins was granted 21,950 stock options on 06/25/2025.
Terms of the option: the exercise price is $2.05 per share, with 100 % of the underlying shares vesting on the earlier of (i) the first anniversary of the grant date or (ii) the company’s 2026 annual meeting, provided Mr. Collins remains in service until that date. The options expire on 06/24/2035.
Ownership impact: Following this grant, Collins directly holds 21,950 derivative securities (options) and no non-derivative transactions were reported. No shares were sold or otherwise disposed of in this filing.
Sign-off: The filing was executed by attorney-in-fact Timothy Lu and dated 06/27/2025.
Form 4 overview: On 06/25/2025, Senti Biosciences (ticker SNTI) reported granting director Feng Hsiung a stock option for 21,950 common shares at an exercise price of $2.05 per share.
The option, filed on 06/27/2025, vests 100 % on the earlier of (i) the first anniversary of the grant or (ii) the 2026 annual shareholders’ meeting, subject to continued board service. It carries a 10-year term with an expiration date of 06/24/2035.
No open-market purchase or sale of common shares occurred; the transaction is strictly an equity-based compensation award. After the grant, Mr. Hsiung beneficially owns 21,950 derivative securities, and the filing shows no change to his direct or indirect ownership of outstanding common shares. The disclosure does not reference a Rule 10b5-1 trading plan.
Investor take-away: This is a routine director compensation event that modestly aligns board incentives with shareholder value. It creates potential dilution only if exercised and has no immediate impact on cash flow, operations, or the company’s financial outlook. The Form 4 contains no earnings or operational data.